In numerous bacterial species, the surface is adorned with a variety of polysaccharides. Those substances manifest as capsules, glycoproteins, or glycolipids. The saccharides are divided into two parts: the core oligosaccharide, adjacent to the lipid portion, and the O-polysaccharide. The O-polysaccharide is like the capsular polysaccharide that either is a homopolymer or comprises repeating units, which may range from di- to hexasaccharide. While capsular polysaccharide vaccines have been developed against those organisms, they often are useless in generating an obvious immune response in young and immunocompromised individuals. Generally speaking, polysaccharide antigens result in a T-independent immune response without memory. Besides, they exhibit weak immunogenicity, particularly at the extremes of life. To address these limitations, conjugate vaccines are developed. This strategy enables the induction of a T-dependent immune response against these antigens, thus enhancing their immunogenicity.
Fig.1 Antibody production in response to polysaccharide antigens. (Perera, et al., 2021)
CD BioGlyco is good at the development of conjugate vaccines by linking capsular polysaccharides to Carrier Proteins. There are many capsular polysaccharides of encapsulated bacterial pathogens that give rise to an effective immune response in humans for vaccine production. However, bacterial capsular polysaccharides often contain some impurities such as bacterial proteins, nucleic acids, and endotoxins. Therefore, it is important to purify the capsular polysaccharide by removing these impurities. We provide diverse approaches to produce and purify various bacterial capsular polysaccharides. Subsequently, we will characterize the polysaccharides we produced to ensure quality through a variety of scientific and technological means. We also possess diverse carriers for the development of conjugate vaccines, including Traditional Protein Carriers, New Protein Carriers, and Nanoparticle (NP) Carriers.
CD BioGlyco is a leader in glycobiology that offers groundbreaking solutions through the innovative Glyco™ Vaccine Development Platform. We have many years of experience in Carbohydrate-based Vaccine Development. Besides, we conduct precise manipulation and characterization of polysaccharide antigens to ensure optimal immunogenicity. We also provide diverse carriers that are linked with our polysaccharides for the glycoconjugate vaccine development. If our services arouse your interest, we encourage you to contact us for additional details.
Reference:
